


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously presented) A compound of general formula I,



or a pharmaceutically acceptable salt or hydrate thereof, wherein R represents unsubstituted or substituted lower alkyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted lower alkylamino or a saturated five or six membered heterocyclic group containing one or two nitrogen atoms.

2. (Original) A compound according to claim 1, wherein R represents unsubstituted or substituted lower alkyl or unsubstituted or substituted aryl.


3. (Original) A compound according to claim 2, wherein R represents unsubstituted or substituted lower alkyl.

4. (Previously presented) A compound according to claim 3, said compound being 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

5. (Previously presented) A compound according to claim 3, said compound being 4-(6-acetoxyindan-1-ylmethyl)-1*H*-imidazol-1-ium chloride.

6. (Previously presented) A compound according to claim 3, said compound being 4-(6-butyryloxyindan-1-ylmethyl)-1*H*-imidazol-1-ium chloride.


7. (Currently Amended) A method for the treatment of hypertension, glaucoma, migraine, diarrhea, ischemia, addiction to a chemical substance, hypotension, shock, cardiopulmonary resuscitation, ~~a micturition disorder~~, a withdrawal syndrome, congestive heart failure, anxiety ~~or a neurological, muscleskeletal, psychiatric or cognition disorder~~, or for achieving sedation or analgesia, or for reducing nasal congestion, or for achieving anesthesia with an adjunct, which comprises administering to a mammal in need thereof an effective amount of a compound of formula I,



or a pharmaceutically acceptable salt or hydrate thereof, wherein R is as defined in claim 1.

8. (Previously presented) A method according to claim 7, wherein the compound is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

9. (Previously presented) A pharmaceutical composition which comprises as an active agent a compound of formula I,



or a pharmaceutically acceptable salt or hydrate thereof, wherein R is as defined in claim 1, and optionally a pharmaceutically acceptable excipient.

10. (Original) A pharmaceutical composition according to claim 9, wherein the compound is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

Claims 11-12 (Canceled)